Giant Biogene Holding Co., Ltd. (2367.HK)
HKD 51.95
(0.0%)
HKD 51.95
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 1.64 Billion | 931.63 Million | 692.4 Million | 834.12 Million | 656.45 Million |
| Net Income | 1.74 Billion | 1.17 Billion | 972.91 Million | 973.24 Million | 676.99 Million |
| Depreciation & Amortization | 34.17 Million | 27.62 Million | 24.21 Million | 22.29 Million | 17.88 Million |
| Deferred income taxes | - | - | -253.95 Million | -277.5 Million | - |
| Stock-based compensation | 20.51 Million | 17.66 Million | 16.48 Million | 592 Thousand | - |
| Change in working capital | 127.81 Million | -131.67 Million | -57.84 Million | 125.39 Million | 35.84 Million |
| Other non-cash items | -47.37 Million | -159.73 Million | -9.4 Million | -9.88 Million | -74.26 Million |
| Investing Cash Flow | -527.28 Million | -858.73 Million | 1.56 Billion | -521.11 Million | -589.84 Million |
| Investments in PPE | -228.43 Million | -153.24 Million | -111.19 Million | -76.33 Million | -114.9 Million |
| Acquisitions | 33.13 Million | - | 130 Thousand | 825 Thousand | 184 Thousand |
| Investment purchases | -1.05 Billion | -2.19 Billion | -3.92 Billion | -5.08 Billion | -1.49 Billion |
| Sales/Maturities of investments | 678.82 Million | 1.48 Billion | 5.37 Billion | 4.39 Billion | 984.2 Million |
| Other Investing Activities | -300.98 Million | 13.15 Million | 227.11 Million | 241.33 Million | 31.85 Million |
| Financing Cash Flow | 51.8 Million | -5.78 Billion | 4.47 Billion | -17.52 Million | -2.16 Million |
| Debt repayment | -1.04 Million | -186 Thousand | - | - | - |
| Dividends payments | - | -367.46 Million | -2.55 Billion | - | - |
| Common Stock Repurchased | - | -6.23 Billion | - | - | - |
| Common Stock Issuance | 56.39 Million | 583.5 Million | 57 Thousand | - | - |
| Other Financing Activities | 8.9 Million | 230.22 Million | 7.02 Billion | -17.52 Million | -2.16 Million |
| Accounts receivables | -32.58 Million | -3.63 Million | -11.16 Million | -37.5 Million | -5.31 Million |
| Accounts payables | - | 3.63 Million | 11.16 Million | 37.5 Million | 5.31 Million |
| Inventory | -17.76 Million | -94.35 Million | -24.6 Million | -14.44 Million | -9.59 Million |
| Other working capital | 75 Million | -37.31 Million | -33.23 Million | 139.83 Million | 45.44 Million |
| Cash at beginning of period | 1.33 Billion | 7.1 Billion | 367.8 Million | 72.32 Million | 7.87 Million |
| Cash at end of period | 2.5 Billion | 1.33 Billion | 7.1 Billion | 367.8 Million | 72.32 Million |
| Capital Expenditure | -228.43 Million | -153.24 Million | -111.19 Million | -76.33 Million | -114.9 Million |
| Effect of forex changes on cash | 1.09 Million | -55.18 Million | 3.98 Million | - | - |
| Net cash flow / Change in cash | 1.17 Billion | -5.77 Billion | 6.73 Billion | 295.48 Million | 64.44 Million |
| Free Cash Flow | 1.41 Billion | 778.38 Million | 581.21 Million | 757.79 Million | 541.54 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 392.4 Million | 1.74 Billion | 392.4 Million | 333.47 Million | 333.47 Million | 1.17 Billion |
| Depreciation & Amortization | 8.41 Million | 34.17 Million | 8.41 Million | 8.43 Million | 8.43 Million | 27.62 Million |
| Deferred income taxes | - | - | - | -37.26 Million | 7.03 Million | - |
| Stock-based compensation | 5.04 Million | 20.51 Million | 5.04 Million | 5.21 Million | 5.21 Million | 17.66 Million |
| Change in working capital | 612.5 Thousand | 127.81 Million | 612.5 Thousand | 11.71 Million | 11.71 Million | -131.67 Million |
| Other non-cash items | 70.79 Million | -47.37 Million | 70.79 Million | -12.38 Million | -12.38 Million | -159.73 Million |
| Investing Cash Flow | -27.43 Million | -527.28 Million | -27.43 Million | -236.2 Million | -236.2 Million | -858.73 Million |
| Investments in PPE | -19.66 Million | -228.43 Million | -19.66 Million | -93.48 Million | -93.48 Million | -153.24 Million |
| Acquisitions | - | 33.13 Million | - | 42.05 Million | - | - |
| Investment purchases | - | -1.05 Billion | - | -1.07 Billion | - | -2.19 Billion |
| Sales/Maturities of investments | - | 678.82 Million | - | 683 Million | - | 1.48 Billion |
| Other Investing Activities | -7.76 Million | -300.98 Million | -7.76 Million | -142.72 Million | -142.72 Million | 13.15 Million |
| Financing Cash Flow | 30.39 Million | 51.8 Million | 30.39 Million | -4.48 Million | -4.48 Million | -5.78 Billion |
| Debt repayment | - | -1.04 Million | - | - | - | -186 Thousand |
| Dividends payments | - | - | - | - | - | -367.46 Million |
| Common Stock Repurchased | - | - | - | - | - | -6.23 Billion |
| Common Stock Issuance | - | 56.39 Million | - | -14.07 Million | - | 583.5 Million |
| Other Financing Activities | 30.39 Million | 8.9 Million | 30.39 Million | -4.48 Million | -4.48 Million | 230.22 Million |
| Accounts receivables | -5.66 Million | -32.58 Million | -5.66 Million | -10.63 Million | -10.63 Million | -3.63 Million |
| Accounts payables | - | - | - | 21.19 Million | - | 3.63 Million |
| Inventory | -7.26 Million | -17.76 Million | -7.26 Million | -1.62 Million | -1.62 Million | -94.35 Million |
| Other working capital | 13.53 Million | 75 Million | 13.53 Million | 23.96 Million | 23.96 Million | -37.31 Million |
| Cash at beginning of period | - | 1.33 Billion | - | 1.43 Billion | - | 7.1 Billion |
| Cash at end of period | 473.24 Million | 2.5 Billion | 473.24 Million | 1.68 Billion | 113.27 Million | 1.33 Billion |
| Capital Expenditure | -19.66 Million | -228.43 Million | -19.66 Million | -93.48 Million | -93.48 Million | -153.24 Million |
| Effect of forex changes on cash | -6.97 Million | 1.09 Million | -6.97 Million | 7.52 Million | 7.52 Million | -55.18 Million |
| Net cash flow / Change in cash | 473.24 Million | 1.17 Billion | 473.24 Million | 246.73 Million | 113.27 Million | -5.77 Billion |
| Free Cash Flow | 457.59 Million | 1.41 Billion | 457.59 Million | 252.96 Million | 252.96 Million | 778.38 Million |
MGL
EOF
0217
8428
6033
CSMYF